LYCOS RETRIEVER 
Norvasc
built 641 days ago
The antihypertensive efficacy of Norvasc has been demonstrated in a total of 15 double-blind, placebo-controlled, randomized studies involving 800 patients on Norvasc and 538 on placebo. Once daily administration produced statistically significant placebo-corrected reductions in supine and standing blood pressures at 24 hours postdose, averaging about 12/6 mmHg in the standing position and 13/7 mmHg in the supine position in patients with mild to moderate hypertension. Maintenance of the blood pressure effect over the 24-hour dosing interval was observed, with little difference in peak and trough effect. Tolerance was not demonstrated in patients studied for up to 1 year. The 3 parallel, fixed dose, dose response studies showed that the reduction in supine and standing blood pressures was dose-related within the recommended dosing range. Effects on diastolic pressure were similar in young and older patients.
Source:
MORE ABOUT
Norvasc